Table 1.

Patient demographic data by SLCO1B1 c.521T>C genotype^a

Variable	TT genotype	TC genotype	CC genotype	P-value
Baseline screening
Number of evaluable patients	62	27	2
White / Black	53 (85) / 9 (15)	26 (96) / 1 (4)	2 (100) / 0 (0)	0.28
Age (years)	61 (40–77)	65 (42–83)	75 (70–79)	0.22
Sex (male / female)	34 (55) / 28 (45)	17 (63) / 10 (37)	2 (100) / 0 (0)	0.37
Body-surface area (m2)	1.85 (1.40–2.72)	2.01 (1.46–2.40)	1.91 (1.84–1.98)	0.14
ECOG performance status	1 (0–2)	1 (0–1)	1 (1–1)	0.83
Primary tumor site
Breast	20 (32)	4 (15)	0 (0)	0.31
Prostate	15 (24)	8 (30)	2 (100)
Lung	10 (16)	4 (15)	0 (0)
Head and neck	5 (8)	2 (7)	0 (0)
Miscellaneous	12 (20)	9 (33)	0 (0)
Pre-therapy chemistry
Total bilirubin (× ULN)	0.42 (0.17–1.25)	0.42 (0.17–1.25)	0.67 (0.42–0.92)	0.13
Aspartate aminotransferase (× ULN)	0.76 (0.28–4.70)	0.76 (0.30–3.87)	0.86 (0.76–0.97)	0.55
Alanine aminotransferase (× ULN)	0.60 (0.10–6.61)	0.53 (0.18–6.61)	1.14 (0.60–1.68)	0.67
Alkaline phosphatase (× ULN)	0.84 (0.36–8.69)	0.90 (0.34–8.69)	2.22 (0.55–3.88)	0.18
α 1-acid glycoprotein (mg/dL)	133 (60–257)	142 (63–257)	141 (79–202)	0.23

^aContinuous data are given as median with range in parenthesis, and categorical data as number of patients with percentage of the total population in parenthesis.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; ULN, upper limit of institutional normal.